Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report.
Under kv2 2024 levererade Fable Media en nettoomsättning i linje med vår förväntan.
Nettoomsättningen sjönk med 11% på årsbasis drivet av längre säljcykler och en övergång till en part...
Loihde’s Q2 was better than anticipated. Net sales grew a modest 3% to EUR 35.
At the end of September Beyond Frames internal studio will release “Escaping Wonderland” based on “A...
Sales +2%, but EBITA -24% vs. ABGSCe, driven by personnel costs Slower cost reductions than we had t...
Luxbright AB (”Luxbright” eller ”Bolaget”) har presenterat en H1-rapport som illustrerar att det kom...
5% org. sales growth, 7% adj. EBITA growth, neg. cash flow '24e-'26e adj.
Devport levererade en omsättning och resultat för det andra kvartalet i nivå med marknadens förväntn...
Embark Group (f.d. Lucky Games) har publicerat bolagets delårsrapport för det andra kvartalet år 202...
Redeye updates its view on Acarix following its Q2 2024 report.
Mangold uppdaterar cybersäkerhetsbolaget Cyber Security 1 (”CYBER1”).
Redeye updates its estimates and valuation after Navigo’s Q2 2024 report.
Redeye is encouraged by the recent commercial progress, particularly in the Chinese market.
Redeye provides an update following CLS’ Q2 report that fairly aligned with our expectations and did...
InfraCom’s report was weak, and the company faces a cocktail of headwinds.
Redeye states AVTECH’s report was in line with Redeye Research estimate (RRe) on net sales and a sol...
Redeye sees a Q2 report roughly matching our expectations.
Small Q2 beat amid solid underlying performance In strong position to act on opportunities Fair valu...
AcuCort (”AcuCort” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det andra kvartalet 20...
